AUS
NZ
UK
CA
USA
IND
ANGLE plc (LSE:AGL), a leader in liquid biopsy technology, has announced an exciting new partnership with NuProbe USA, Inc., a pioneering genomics and molecular diagnostics firm. This collaboration centers around NuProbe's advanced pan-cancer next generation sequencing (NGS) panel, aimed at enhancing ANGLE’s capabilities in circulating tumor cell (CTC) analysis.
Under the agreement, ANGLE will have the option for an exclusive global license to the NGS panel for use outside of China. This license covers the analysis of CTCs and the combined analysis of CTCs and circulating tumor DNA (ctDNA). As the collaboration begins, NuProbe will transfer the manufacturing of the NGS panel to a larger-scale facility, while ANGLE will conduct internal validation of the initial production batches.
The NGS panel, which has been validated on the Illumina sequencer, is capable of detecting over 6,500 DNA mutations across 61 clinically relevant genes. ANGLE has identified it as the highest performing multi-gene assay among those evaluated. This comprehensive gene analysis includes genes that are often linked to targeted therapies, which are typically identified through tumor tissue or ctDNA assays, aligning with key drug targets being developed by major pharmaceutical companies.
This strategic agreement is expected to significantly accelerate ANGLE's efforts to commercialize its first pan-cancer molecular sequencing assay. This assay will allow for either the analysis of CTC-DNA alone or the dual analysis of CTCs and ctDNA from a single blood sample. The NGS panel provides highly sensitive and specific high-throughput gene analysis, which will be immediately applicable to ANGLE's pharmaceutical services customers and translational researchers utilizing the Parsortix® system.
In the long term, the partnership aims to establish a reliable, minimally invasive method for molecular profiling through liquid biopsy analytes. This advancement has the potential to transform clinical practices, enabling physicians to monitor tumor evolution, assess treatment responses, identify early drug resistance, and track disease progression.
